ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03407079
Recruitment Status : Recruiting
First Posted : January 23, 2018
Last Update Posted : April 19, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) )

Brief Summary:

Background:

Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes.

Objective:

To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how fat cells are metabolized.

Eligibility:

People ages 18-60 who:

  • Are black or Hispanic
  • Weigh more than 110 pounds
  • Have a body mass index of 25-40
  • Do not have a condition that requires drug treatment

Design:

Participants will be screened with:

  • Medical history
  • Physical exam
  • Blood, heart, and urine tests

Participants must not eat or drink anything with artificial sweeteners throughout the study.

Over 7 days, Participants will answer questions, and give daily urine samples and 1 stool sample. Participants will repeat these throughout the study.

Overnight Visit 1: participants will fast starting the night before. They will get breakfast at the visit. The visit includes:

  • An IV will be placed in the arm. Participants will get 2 tablets of medicines. Blood will be drawn several times over 24 hours.
  • A piece of fat tissue may be taken from the abdomen (biopsy).
  • Participants will have a sweet drink. Blood samples will be taken over 2 hours.

Then participants will be randomly assigned to take either a sucralose capsule or placebo. They will take it twice a day for 2 weeks. They will complete two 24-hour food diaries.

Overnight Visit 2 repeats Visit 1 except the biopsy.

Then participants will take the capsules for another 2 weeks.

Overnight Visit 3 repeats Visit 1.

Participants may be contacted by phone within 4 weeks after they finish.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Overweight Other: Sucralose Other: Placebo Phase 2

Detailed Description:

Background:

Consumption of non-nutritive sweeteners (NNS) has dramatically increased worldwide and is more prevalent in women than men. Similarly, obesity rates have continued to rise, most notably in minorities. Since NNS consumption has been linked to obesity, we propose studying NNS effects specifically in minority women.

NNS are frequently consumed in combination with prescription medications. This necessitates the study of possible NNS-drug interactions. The hypothesis that NNS may affect drug absorption and metabolism is based on a rodent study. In 2008, Abou-Donia et al reported that sucralose increased the activity of P-glycoprotein (P-gp), a membrane transporter involved in absorption and distribution of a wide range of pharmacologic compounds, and CYP3A, a cytochrome P-450 enzyme important to the first-pass metabolism of many drugs.

So far, NNS effects in clinical studies were mostly observed after acute (one time) or short term exposure. For example, we and others found increased incretin and insulin concentrations in response to sucralose alone or in combination with acesulfame-potassium prior to a glucose load. The effects were most pronounced in obese African American women. We also found upregulation of inflammatory cytokines in subcutaneous fat biopsies of obese individuals who reported consumption of NNS compared to non-consumers. Whether these hormonal and tissue responses persist after prolonged exposure needs to be investigated. NNS have also been shown to influence the microbial composition of the oral cavity and the gut. However, most data were generated in mice and do not exist in humans.

Aims:

Primary Aim: To determine the effects of sucralose (4 mg/kg/day) administered to overweight and obese minority women for 28 days on drug metabolism using digoxin and midazolam as probes for P-glycoprotein and CYP3A, respectively.

Secondary Aims: To investigate the effects of sucralose on

  1. glucose metabolism and incretin secretion
  2. lipid metabolism
  3. intestinal microflora

Methods:

The study consists of 3 periods. In the first period (run-in, 7 days), participants will be instructed to avoid all NNS (including NNS in cosmetics or health care products). During the second and third periods (14 days each), participants will be randomized to consume either sucralose containing capsules (4 mg/kg/day) or placebo. At the end of each period, the following measurements will be obtained during an overnight hospitalization:

  1. Serial measurements of plasma concentrations of midazolam and digoxin for 24 hours following a single oral dose of each drug
  2. Frequently sampled 2-hour oral glucose tolerance test (OGTT) to measure glucose, insulin, C-peptide, GLP-1, and other gut hormones.

At the end of P1 (run-in, no intervention) and after P3 (sucralose exposure x 4 weeks), subcutaneous fat biopsies will be performed. Stool samples will be obtained throughout.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Actual Study Start Date : April 5, 2018
Estimated Primary Completion Date : August 1, 2020
Estimated Study Completion Date : August 1, 2021

Arm Intervention/treatment
Experimental: Study Arm 1
Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
Other: Sucralose
Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.

Placebo Comparator: Study Arm 2
Participants will receive placebo capsules by mouth for 28 days.
Other: Placebo
Placebo capsule




Primary Outcome Measures :
  1. To explore the effects of sucralose (approx 4 mg/kg x 28 days) on pharmacokinetics of digoxin and midazolam, which are representative examples of P-gp and CYP3A dependent medications. [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Glucose metabolism and incretin secretion [ Time Frame: 28 days ]
  2. Lipid metabolism [ Time Frame: 28 days ]
  3. Intestinal microbiome [ Time Frame: 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

    1. Age: between 18 and 60 years
    2. Female adults who self-identify as Hispanic and/or Black
    3. Body weight greater than 50 kg (110 lb)
    4. Body mass index between 25 kg/m^2 and 40 kg/m^2
    5. Consumption of less than or equal to one 12-ounce beverage sweetened with NNS per month or food equivalent
    6. Healthy with no known active medical condition or illness that requires drug treatment
    7. Able and willing to consume approximately 4 mg/kg sucralose daily or placebo in form of capsules for

    4 weeks

    8. Able and willing to avoid eating grapefruit, parsnips, celery, drinking grapefruit juice or sodas containing quinine (e.g. tonic water) during the study

    9. Able and willing to collect stool specimens

    10. Able and willing to consume digoxin and midazolam during study visits

EXCLUSION CRITERIA:

  1. Current use of prescription or non-prescription medication(s), herbal medications and oral contraceptives are also excluded. Certain exceptions are permitted, including vitamins. Other medications may be permitted at the discretion of the investigators.
  2. Diabetes (fasting blood glucose of 126 mg/dl or higher, or 2-hour blood glucose of 200 or higher on OGTT)
  3. Taken medications that affect blood sugar in the past 3 months or that include antibiotics
  4. GI history, at the discretion of the investigators
  5. Known allergy, sensitivity, or other contraindication to study procedures
  6. ALT or AST more than 1.5 times the upper limit of normal
  7. Abnormal thyroid function or abnormal serum electrolytes & minerals (specifically potassium, calcium, and magnesium)
  8. Narrow angle glaucoma or untreated open angle glaucoma
  9. Regular use of alcohol (more than 1 drink per day) or drug use
  10. History of cardiac abnormalities, especially arrhythmia
  11. Unable or unwilling to cooperate with study procedures
  12. Psychiatric or cognitive disorder that will, in the opinion of the investigators, limit the subject's ability to provide informed consent, or to comply with study procedures
  13. Pregnant, planning to become pregnant or lactating (digoxin and midazolam are Category C and D medications, respectively).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03407079


Contacts
Contact: Kristina I Rother, M.D. (301) 435-4639 kristinar@intra.niddk.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Kristina I Rother, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Additional Information:
Publications:
Responsible Party: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT03407079     History of Changes
Other Study ID Numbers: 180047
18-DK-0047
First Posted: January 23, 2018    Key Record Dates
Last Update Posted: April 19, 2018
Last Verified: January 12, 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ):
Drug Metabolism
Artificial Sweetner
P-Glycoprotein
Cytochrome P 450
Microbiome

Additional relevant MeSH terms:
Overweight
Body Weight
Signs and Symptoms